High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER
Executive Summary
There are as many rare disease patients as there are diabetics, Cigna’s Steve Miller notes, arguing that exorbitant prices for each treatment could drive counterproductive categorical exclusions by payers.
You may also be interested in...
Value-Based Agreements For Cancer Drugs: Are Manufacturers Spinning Their Wheels?
Lack of progress in advancing contracts that align value with price may encourage more external price controls, some experts suggest.
US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
The Cost Of ‘Stacking’ Orphan Indications And A Case For Reform
Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.